In April 2024, the Federal Trade Commission announced that it was expanding its campaign against pharmaceutical manufacturers improper or inaccurate listing of patents in the Food and Drug Administrations (FDA) Orange Book, disputing junk patent listings for diabetes, weight loss, asthma, and COPD drugs, including Novo Nordisk Inc.s blockbuster weight-loss drug, Ozempic. If the administration revoked Novos extension, patent protection for semaglutide will expire in 2026 as it is scheduled to do in many other countries
Obesity is associated with numerous cardiometabolic complications and contributes to increased overall mortality [4, 5]
Silver nanoparticles in cancer: therapeutic efficacy and toxicity
Independent quality testing of these mystery drugs is hindered by the lack of a U.S
Advanced Delivery Methods Our advanced delivery methods feature multiple formulations such as intravenous and intramuscular injection delivery options which optimize both bioavailability and treatment effectiveness
